secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001171843-24-000966
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).
- Revenue $4.1M in Q4 2023 vs $1.6M in Q4 2022, primarily from Rockefeller University manufacturing agreements.
- Cash, cash equivalents and marketable securities $423.6M at Dec 31, 2023 vs $235.3M at Sep 30, 2023; $216.2M raised in Nov 2023 offering.
- Barzolvolimab: Positive Phase 2 CSU 12-week data; Phase 3 CSU studies expected to start summer 2024; 52-week data in 2H 2024.
- Phase 2 CIndU enrollment nearing completion (data 2H 2024); Phase 2 PN study to start early 2024; cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/0001171843-24-000966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184324000966/f8k_022524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer